Ancrod project – From raw venom to highly purified drug substance
Ancrod is isolated as a biologically active substance from the venom of the Malayan Pit Viper (Calloselasma rhodostoma) at Nordmark’s biocentre. Ancrod is a fibrinogen splitting enzyme (fibrinogenase), which may be therapeutically significant in a number of indications. Fibrinogenase works by lowering the level of fibrinogen in blood, leading to a reduction of blood viscosity.
The starting material for the production of fibrinogenase is the dried venom obtained from the Snake Farm, which was specially designed and built for snake breeding and husbandry. Ancrod is isolated in clean rooms and under GMP conditions, using a multi-step protein purification process involving filtration and chromatography steps. These steps are followed by the formulation and final bottling in vials to produce clinical test samples. Ancrod is currently under investigation in a Phase 2 clinical trial for sudden sensorineural hearing loss (SSHL).